About Alzinova
Alzinova AB is a Swedish pharmaceutical enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers.
Press Releases
-
2020-03-05
Alzinova appoints new Chief Financial Officer
-
2020-03-05
Alzinova tillsätter ny Chief Financial Officer
-
2020-02-27
Communiqué from the Extraordinary General Meeting of Alzinova AB on 27 February 2020
-
2020-02-27
Kommuniké från extra bolagsstämma i Alzinova AB den 27 februari 2020
-
2020-02-27
Complete proposals to the Extraordinary General Meeting of Alzinova later today, 27 February 2020
-
2020-02-27
Fullständiga förslag inför Alzinovas extra bolagsstämma senare idag den 27 februari 2020